secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2022-01-31T23:59:59+00:00
Accession:  0001193125-22-023401
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen amends Aimovig collaboration with Novartis, ends US royalties and cost-sharing
--------------------------------------------------------------------------------

- Novartis gets sole commercialization rights for Aimovig outside US and Japan; Amgen ends royalty payments on US sales.
- U.S. Collaboration Agreement terminated Jan 31, 2022; parties no longer share US commercialization costs.
- Amgen's share of Franchise Product 1 (Aimovig) development costs capped at $[***] aggregate; thereafter split 50/50.
- Litigation between the parties resolved concurrently with these amendments.
- Novartis to fund US Medical Affairs activities until a defined completion date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000119312522023401/0001193125-22-023401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000119312522023401/d275986d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-023401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer